,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-12-24 02:17:00,There is good news from Baxter International Inc. ( BAX ).,0.8244335651397705,0.017731817439198494,0.15783466398715973,positive,0.8067017197608948
1,2013-12-24 02:17:00,The Illinois-based global medical products and services company announced receipt of the U.S. Food and Drug Administration (FDA) approval for its FEIBA (Anti-Inhibitor Coagulant Complex) treatment as well as CE marking in Europe for the VIVIA hemodialysis (HD) system.,0.9178090691566467,0.013475919142365456,0.06871501356363297,positive,0.9043331742286682
2,2013-12-24 02:17:00,The news resulted in a 2.7% rise in the stock till yesterday.,0.9484512209892273,0.02096347138285637,0.03058529831469059,positive,0.9274877309799194
3,2013-12-24 02:17:00,"FEIBA is the first and only FDA-approved treatment for routine prophylaxis that controls the frequency of bleeding episodes in hemophilia A or B patients, who have developed inhibitors.",0.21265189349651337,0.008516615256667137,0.7788314819335938,neutral,0.20413528382778168
4,2013-12-24 02:17:00,Inhibitors are antibodies produced by the body's immune system in response to factor replacement treatment.,0.028261825442314148,0.026291994377970695,0.9454461336135864,neutral,0.0019698310643434525
5,2013-12-24 02:17:00,About one-third of previously untreated patients with hemophilia A are at risk of developing inhibitors.,0.0721752718091011,0.5485460162162781,0.37927868962287903,negative,-0.47637075185775757
6,2013-12-24 02:17:00,Development of inhibitors is a major complication associated with hemophilia treatment.,0.033352456986904144,0.3445258140563965,0.6221218109130859,neutral,-0.31117334961891174
7,2013-12-24 02:17:00,Inhibitors lead to lack of response to treatments and their presence increases the risk of developing more complications.,0.07504832744598389,0.6339483857154846,0.2910033166408539,negative,-0.5589000582695007
8,2013-12-24 02:17:00,"A pivotal Phase III study, FEIBA PROOF, is responsible for the approval.",0.17943359911441803,0.006566366646438837,0.8140000104904175,neutral,0.17286723852157593
9,2013-12-24 02:17:00,The study showed a 72% reduction in median annual bleed rate (ABR) compared to treatment with an on-demand regimen.,0.03452277183532715,0.9521801471710205,0.0132970679551363,negative,-0.9176573753356934
10,2013-12-24 02:17:00,"VIVIA hemodialysis system is capable of delivering frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy1.",0.06791170686483383,0.005514892283827066,0.9265733957290649,neutral,0.0623968131840229
11,2013-12-24 02:17:00,It is designed with the patient as the primary operator.,0.026241783052682877,0.006269271019846201,0.9674889445304871,neutral,0.019972512498497963
12,2013-12-24 02:17:00,BAX will introduce VIVIA in a few number of European dialysis clinics in 2014 to allow patients and healthcare providers become familiar with the system.,0.3461472690105438,0.007905138656497002,0.6459476351737976,neutral,0.33824214339256287
13,2013-12-24 02:17:00,The company plans to expand launching the product to other European nations in 2015.,0.7715340852737427,0.013424159027636051,0.21504171192646027,positive,0.7581099271774292
14,2013-12-24 02:17:00,"Last month, Baxter entered a global licensing agreement with Cell Therapeutics, Inc. ( CTIC ) to jointly develop and commercialize JAK2/FLT3 inhibitor pacritinib that fights against genetic mutations linked to myelofibrosis, leukemia and some tumors.",0.919337809085846,0.013905919156968594,0.06675629317760468,positive,0.905431866645813
15,2013-12-24 02:17:00,"As per the agreement, BAX gained the commercialization rights for all indications for pacritinib outside the U.S. while it jointly commercializes with CTIC in the U.S.",0.6920413970947266,0.009707305580377579,0.29825130105018616,positive,0.6823340654373169
16,2013-12-24 02:17:00,"Following the announcement, shares of Baxter rose 0.2% to $68.82 after the market closed yesterday.",0.9497319459915161,0.02076965570449829,0.029498372226953506,positive,0.9289622902870178
17,2013-12-24 02:17:00,"According to the agreement, Baxter will provide an upfront payment of $60 million, including a $30 million equity investment in CTIC.",0.28563442826271057,0.007841479033231735,0.7065240740776062,neutral,0.27779296040534973
18,2013-12-24 02:17:00,"Moreover, Cell Therapeutics will receive clinical, regulatory, and commercial launch milestone payments of up to $112 million ($40 million of which relates to clinical milestones likely to be achieved in 2014) from BAX.",0.8214002847671509,0.011366271413862705,0.16723346710205078,positive,0.8100340366363525
19,2013-12-24 02:17:00,"Baxter posted a 4% rise in third-quarter 2013 adjusted earnings per share to $1.19, in line with the Zacks Consensus Estimate.",0.9568668603897095,0.020334504544734955,0.022798653692007065,positive,0.9365323781967163
20,2013-12-24 02:17:00,The third-quarter results were also within the company's earlier stated guidance of $1.18-$1.21.,0.15635500848293304,0.031796447932720184,0.8118484616279602,neutral,0.12455856055021286
21,2013-12-24 02:17:00,"Revenues for the quarter went up 9% to $3,774 million but slightly missed the Zacks Consensus Estimate of $3,795 million.",0.6288930177688599,0.3394487500190735,0.03165822476148605,positive,0.2894442677497864
22,2013-12-24 02:17:00,"On an organic basis (excluding Gambro that contributed $100 million), revenues climbed 6%.",0.9563031196594238,0.021078266203403473,0.02261851541697979,positive,0.9352248311042786
23,2013-12-24 02:17:00,Foreign currency did not impact revenues in the quarter.,0.020657340064644814,0.30068647861480713,0.6786562204360962,neutral,-0.28002914786338806
24,2013-12-24 02:17:00,"On a geographic basis, revenues in the U.S. as well as internationally improved 9% to $1,642 million and $2,132 million, respectively.",0.9584024548530579,0.023768620565533638,0.017828956246376038,positive,0.9346338510513306
25,2013-12-24 02:17:00,"For the fourth quarter of 2013, BAX expects revenue growth in the range of 14% to 15% (12% to 13% at CER).",0.9206551909446716,0.013318032957613468,0.06602680683135986,positive,0.9073371291160583
26,2013-12-24 02:17:00,"This includes the impact of the Gambro AB acquisition, amounting to $400 million.",0.01453095767647028,0.009151864796876907,0.9763171672821045,neutral,0.005379092879593372
27,2013-12-24 02:17:00,Adjusted earnings per share are expected in the band of $1.24 to $1.26.,0.1244276612997055,0.016057271510362625,0.8595150113105774,neutral,0.10837039351463318
28,2013-12-24 02:17:00,"The Zacks Consensus Estimate for revenues and earnings per share are pegged at $4,249 million and $1.25 respectively, for the quarter.",0.030444232746958733,0.022005874663591385,0.9475498795509338,neutral,0.008438358083367348
29,2013-12-24 02:17:00,"Baxter affirmed its earnings forecast for 2013, which includes the impact of its Gambro acquisition.",0.7018030285835266,0.020357776433229446,0.2778392434120178,positive,0.6814452409744263
30,2013-12-24 02:17:00,"For 2013, the company expects reported revenue growth of 6% (7% at CER).",0.9311116337776184,0.01417455356568098,0.05471384525299072,positive,0.9169370532035828
31,2013-12-24 02:17:00,"Excluding the impact of foreign exchange rate and the Gambro acquisition, Baxter continues to expect sales growth of approximately 4% (or 3% including the impact of foreign currency).",0.9239157438278198,0.013340328820049763,0.06274397671222687,positive,0.9105753898620605
32,2013-12-24 02:17:00,The company expects to generate revenues from the Gambro acquisition of approximately $500 million for the year.,0.7107205986976624,0.010505997575819492,0.27877336740493774,positive,0.7002146244049072
33,2013-12-24 02:17:00,"Moreover, the company anticipates adjusted earnings per share in the range of $4.65 to $4.67 for 2013.",0.2953239977359772,0.015084892511367798,0.689591109752655,neutral,0.2802391052246094
34,2013-12-24 02:17:00,The Zacks Consensus Estimate for 2013 earnings per share of $4.66 lies within the guided range.,0.126932293176651,0.01754300482571125,0.8555247187614441,neutral,0.1093892902135849
35,2013-12-24 02:17:00,"Baxter continues to expect cash flow from operations to be $3,300 million for 2013.",0.0817229375243187,0.009216481819748878,0.909060537815094,neutral,0.07250645756721497
36,2013-12-24 02:17:00,The recent collaboration with Cell Therapeutics is expected to benefit Baxter's oncology business.,0.9276277422904968,0.013738930225372314,0.058633312582969666,positive,0.9138888120651245
37,2013-12-24 02:17:00,It will also strengthen its position as a solution provider for hematology and rare diseases.,0.938464343547821,0.013971480540931225,0.047564227133989334,positive,0.9244928359985352
38,2013-12-24 02:17:00,"Currently, Baxter has a Zacks Rank #4 (Sell).",0.14008373022079468,0.026101212948560715,0.8338150382041931,neutral,0.11398251354694366
39,2013-12-24 02:17:00,"Better-ranked medical product stocks include NuVasive, Inc. ( NUVA ) and Chimerix, Inc. ( CMRX ).",0.5138713121414185,0.018242502585053444,0.46788620948791504,positive,0.49562880396842957
40,2013-12-24 02:17:00,NuVasive sports a Zacks Rank #1 (Strong Buy) while Chimerix carries a Zacks Rank #2 (Buy).,0.501797616481781,0.021916383877396584,0.4762859642505646,positive,0.479881227016449
41,2013-12-24 02:17:00,To read this article on Zacks.com click here.,0.01796119473874569,0.019245078787207603,0.9627937078475952,neutral,-0.001283884048461914
42,2013-12-24 02:17:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
